

Acute Lymphocytic Leukemia - Pipeline Review, H2 2020

<https://marketpublishers.com/r/AA11B2228A19EN.html>

Date: November 2020

Pages: 1809

Price: US\$ 2,500.00 (Single User License)

ID: AA11B2228A19EN

Abstracts

Acute Lymphocytic Leukemia - Pipeline Review, H2 2020

SUMMARY

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Acute Lymphocytic Leukemia - Pipeline Review, H2 2020, provides an overview of the Acute Lymphocytic Leukemia (Oncology) pipeline landscape.

Acute lymphocytic leukemia (ALL) is the cancer of the white blood cells due to the production of a large number of immature lymphocytes thus blocking the production of normal blood cells. It enters the blood stream and rapidly progress to other parts of the body such as spleen, lymph nodes and liver. Risk factors for ALL include exposure to radiation or chemicals, age, virus infections and genetic factors. Symptoms include anemia, frequent infections, easy bruising, bone pain and breathing problems. Treatment includes chemotherapy, transfusions, transplant and medications.

REPORT HIGHLIGHTS

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Acute Lymphocytic Leukemia - Pipeline Review, H2 2020, provides comprehensive information on the therapeutics under development for Acute Lymphocytic Leukemia (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Acute Lymphocytic Leukemia (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Phase 0, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 2, 6, 91, 82, 10, 8, 104, 13 and 4 respectively. Similarly, the Universities portfolio in Phase III, Phase II, Phase I, Phase 0, Preclinical, Discovery and Unknown stages comprises 2, 38, 29, 2, 30, 2 and 1 molecules, respectively.

Acute Lymphocytic Leukemia (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE

The pipeline guide provides a snapshot of the global therapeutic landscape of Acute Lymphocytic Leukemia (Oncology).

The pipeline guide reviews pipeline therapeutics for Acute Lymphocytic Leukemia (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.

The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

The pipeline guide reviews key companies involved in Acute Lymphocytic Leukemia (Oncology) therapeutics and enlists all their major and minor projects.

The pipeline guide evaluates Acute Lymphocytic Leukemia (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

The pipeline guide reviews latest news related to pipeline therapeutics for Acute Lymphocytic Leukemia (Oncology)

REASONS TO BUY

Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

Find and recognize significant and varied types of therapeutics under development for Acute Lymphocytic Leukemia (Oncology).

Classify potential new clients or partners in the target demographic.

Develop tactical initiatives by understanding the focus areas of leading companies.

Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

Formulate corrective measures for pipeline projects by understanding Acute Lymphocytic Leukemia (Oncology) pipeline depth and focus of Indication therapeutics.

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand

business potential and scope.

Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Contents

Introduction

Acute Lymphocytic Leukemia- Overview

Acute Lymphocytic Leukemia- Therapeutics Development

Acute Lymphocytic Leukemia- Therapeutics Assessment

Acute Lymphocytic Leukemia- Companies Involved in Therapeutics Development

Acute Lymphocytic Leukemia- Drug Profiles

Acute Lymphocytic Leukemia- Dormant Projects

Acute Lymphocytic Leukemia- Discontinued Products

Acute Lymphocytic Leukemia- Product Development Milestones

Appendix

List Of Tables

LIST OF TABLES

Number of Products under Development for Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia), H2 2020

Number of Products under Development by Companies, H2 2020

Number of Products under Development by Universities/Institutes, H2 2020

Products under Development by Companies, H2 2020

Products under Development by Universities/Institutes, H2 2020

Number of Products by Stage and Target, H2 2020

Number of Products by Stage and Mechanism of Action, H2 2020

Number of Products by Stage and Route of Administration, H2 2020

Number of Products by Stage and Molecule Type, H2 2020

Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by 4SC AG, H2 2020

Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by AbbVie Inc, H2 2020

Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by Actinium Pharmaceuticals Inc, H2 2020

Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by ADC Therapeutics SA, H2 2020

Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by Adlai Nortye Biopharma Co Ltd, H2 2020

Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by Aeglea BioTherapeutics Inc, H2 2020

Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by Alkido Pharma Inc, H2 2020

Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by Aileron Therapeutics Inc, H2 2020

Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by AIMM Therapeutics BV, H2 2020

Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by Aleta Biotherapeutics Inc, H2 2020

Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by Allterum Therapeutics LLC, H2 2020

Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by Amgen Inc, H2 2020

Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by

Angiocrine Bioscience Inc, H2 2020

Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by Anhui Anke Biotechnology (Group) Co Ltd, H2 2020

Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by Apexian Pharmaceuticals Inc, H2 2020

Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by Applied Therapeutics Inc, H2 2020

Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by AstraZeneca Plc, H2 2020

Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by Atara Biotherapeutics Inc, H2 2020

Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by AUM Biosciences Pte Ltd, H2 2020

Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by Autolus Therapeutics Plc, H2 2020

Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by Avalon GloboCare Corp, H2 2020

Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by AVM Biotechnology LLC, H2 2020

Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by Ayala Pharmaceuticals Inc, H2 2020

Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by Beam Therapeutics Inc, H2 2020

Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by Beijing Immunochina Pharmaceuticals Co Ltd, H2 2020

Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by Bellicum Pharmaceuticals Inc, H2 2020

Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by Bio-Cancer Treatment International Ltd, H2 2020

Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by Bio-Path Holdings Inc, H2 2020

Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by Bioceltech Therapeutics Ltd, H2 2020

Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by Biocure Technology Inc, H2 2020

Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by BioSight Ltd, H2 2020

Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by Bristol-Myers Squibb Co, H2 2020

Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by Cambridge Innovation Technologies Consulting Ltd, H2 2020

Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by CanBas Co Ltd, H2 2020

Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by Caribou Biosciences Inc, H2 2020

Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by CARsgen Therapeutics Ltd, H2 2020

Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by CASI Pharmaceuticals Inc, H2 2020

Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by Collectis SA, H2 2020

Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by Cellestia Biotech AG, H2 2020

Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by Cellipse SAS, H2 2020

Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by Cellular Biomedicine Group Inc, H2 2020

Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by Celularity Inc, H2 2020

Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by China Immunotech (Beijing) Biotechnology Co Ltd, H2 2020

Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by China Immunotech Co Ltd, H2 2020

Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by Chongqing Precision Biotech Co Ltd, H2 2020

Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by ColImmune Inc, H2 2020

Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by ConverGene LLC, H2 2020

Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by Cyclacel Pharmaceuticals Inc, H2 2020

Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by Cyteir Therapeutics Inc, H2 2020

Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by Daiichi Sankyo Co Ltd, H2 2020

Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by Delta-Fly Pharma Inc, H2 2020

Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by

DevaCell Inc, H2 2020

Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by
Dialectic Therapeutics Inc, H2 2020

Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by
Diazon Pharmaceuticals Inc, H2 2020

Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by
DiNonA Inc, H2 2020

Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by Elf
Zone Inc, H2 2020

Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by
Enzyme by Design Inc, H2 2020

Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by
Epizyme Inc, H2 2020

Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by
ERYTECH Pharma SA, H2 2020

Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by
Eureka Therapeutics Inc, H2 2020

Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by Evive
Biotech, H2 2020

Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by
ExCellThera Inc, H2 2020

Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by F.
Hoffmann-La Roche Ltd, H2 2020

Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by Fate
Therapeutics Inc, H2 2020

Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by
Felicitex Therapeutics Inc, H2 2020

Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by
Fusion Pharma LLC, H2 2020

Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by
Gamida Cell Ltd, H2 2020

Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by
GEMoAB Monoclonals GmbH, H2 2020

Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by
Generium, H2 2020

Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by
Genexine Inc, H2 2020

Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by
Gilead Sciences Inc, H2 2020

Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by Gmax Biopharm Ltd, H2 2020

Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by Gracell Biotechnology Ltd, H2 2020

Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by GT Biopharma Inc, H2 2020

Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by Guangzhou Bio-gene Technology Co Ltd, H2 2020

Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by Hangzhou Minsheng Pharmaceutical Group Co Ltd, H2 2020

Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by Hebei Senlang Biotechnology Inc Ltd, H2 2020

Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by HemoGenyx Pharmaceuticals Plc, H2 2020

Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by Henan Honghui Biotechnology Co Ltd, H2 2020

Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by HighPass Bio Inc, H2 2020

Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by Hillstream BioPharma Inc, H2 2020

Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by Zovis Pharmaceuticals, H2 2020

Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Dormant Projects, H2 2020

Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Discontinued Products, H2 2020

List Of Figures

LIST OF FIGURES

Number of Products under Development for Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia), H2 2020

Number of Products under Development by Companies, H2 2020

Number of Products under Development by Universities/Institutes, H2 2020

Number of Products by Top 10 Targets, H2 2020

Number of Products by Stage and Top 10 Targets, H2 2020

Number of Products by Top 10 Mechanism of Actions, H2 2020

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2020

Number of Products by Top 10 Routes of Administration, H2 2020

Number of Products by Stage and Top 10 Routes of Administration, H2 2020

Number of Products by Top 10 Molecule Types, H2 2020

Number of Products by Stage and Top 10 Molecule Types, H2 2020

I would like to order

Product name: Acute Lymphocytic Leukemia - Pipeline Review, H2 2020

Product link: <https://marketpublishers.com/r/AA11B2228A19EN.html>

Price: US\$ 2,500.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/AA11B2228A19EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970